X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
azd9291 (338) 338
oncology (198) 198
index medicus (172) 172
mutation (163) 163
humans (146) 146
gefitinib (140) 140
acquired-resistance (135) 135
lung cancer (113) 113
osimertinib (104) 104
resistance (103) 103
lung neoplasms - drug therapy (99) 99
carcinoma, non-small-cell lung - drug therapy (92) 92
cell lung-cancer (91) 91
t790m (85) 85
epidermal growth factor (84) 84
erlotinib (78) 78
cancer (76) 76
chemotherapy (76) 76
lung neoplasms - genetics (74) 74
lung cancer, non-small cell (73) 73
egfr (71) 71
mutations (71) 71
erbb receptors - genetics (66) 66
tyrosine (66) 66
carcinoma, non-small-cell lung - genetics (65) 65
respiratory system (64) 64
epidermal growth factor receptors (60) 60
non-small cell lung cancer (59) 59
inhibitors (57) 57
protein kinase inhibitors - pharmacology (57) 57
female (56) 56
lung neoplasms - pathology (56) 56
carcinoma, non-small-cell lung - pathology (55) 55
nsclc (55) 55
open-label (54) 54
respiratory tract diseases (53) 53
protein kinase inhibitors - therapeutic use (51) 51
male (49) 49
tyrosine kinase inhibitors (49) 49
kinases (47) 47
antineoplastic agents - therapeutic use (46) 46
cell line, tumor (46) 46
non-small cell lung carcinoma (46) 46
therapy (46) 46
1st-line treatment (45) 45
animals (45) 45
erbb receptors - antagonists & inhibitors (44) 44
patients (44) 44
adenocarcinoma (43) 43
drug resistance, neoplasm - genetics (41) 41
protein-tyrosine kinase (39) 39
antineoplastic agents - pharmacology (38) 38
afatinib (37) 37
care and treatment (37) 37
genetic aspects (37) 37
middle aged (37) 37
drug resistance (35) 35
mechanisms (35) 35
piperazines - therapeutic use (35) 35
analysis (34) 34
epidermal growth factor receptor (34) 34
receptor, epidermal growth factor - antagonists & inhibitors (34) 34
receptor, epidermal growth factor - genetics (34) 34
aged (33) 33
cell biology (33) 33
cancer therapies (31) 31
t790m mutation (31) 31
biochemistry & molecular biology (30) 30
growth-factor receptor (30) 30
chemistry, medicinal (29) 29
metastasis (29) 29
tumors (29) 29
adult (28) 28
egfr mutation (28) 28
development and progression (27) 27
drug resistance, neoplasm (27) 27
pharmacology & pharmacy (27) 27
receptor (27) 27
tki (27) 27
mice (26) 26
cell proliferation - drug effects (25) 25
drug resistance, neoplasm - drug effects (25) 25
egfr inhibitors (25) 25
inhibitor (25) 25
tyrosine kinase inhibitor (25) 25
activation (24) 24
lung neoplasms - metabolism (24) 24
medicine, research & experimental (24) 24
plasma (24) 24
research (24) 24
carcinoma, non-small-cell lung - metabolism (23) 23
egfr-tki (23) 23
kinase inhibitors (23) 23
piperazines - pharmacology (23) 23
apoptosis (22) 22
heterogeneity (22) 22
lung-cancer (22) 22
multicenter (22) 22
neoplasms. tumors. oncology. including cancer and carcinogens (22) 22
biopsy (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 11/2018, Volume 36, Issue 33, pp. 3290 - 3297
PurposeWe report CNS efficacy of osimertinib versus standard epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with... 
SURVIVAL | IMPACT | THERAPY | EFFICACY | ONCOLOGY | BRAIN METASTASES | ACQUIRED-RESISTANCE | AZD9291
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 03/2019, Volume 62, Issue 5, pp. 2843 - 2848
The protein kinase MKK7 is linked to neuronal development and the onset of cancer. The field, however, lacks high-quality functional probes that would allow... 
RESISTANCE | IRREVERSIBLE INHIBITORS | CHEMISTRY, MEDICINAL | MKK4 | AZD9291
Journal Article
Cancer Discovery, ISSN 2159-8274, 12/2018, Volume 8, Issue 12, pp. 1529 - 1539
We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired CCDC6-RET fusion. Although RET fusions have been... 
LUNG-CANCER | CABOZANTINIB | TKI | ONCOLOGY | MUTATION | ERLOTINIB | AZD9291
Journal Article
Translational Cancer Research, ISSN 2218-676X, 2017, Volume 6, Issue S1, pp. S61 - S64
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2018, Volume 24, Issue 22, pp. 5610 - 5621
Purpose: Because of emergence of resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), no targeted treatments are available for... 
TYROSINE KINASE INHIBITORS | GEFITINIB | AMPLIFICATION | ONCOLOGY | MUTATION | ACQUIRED-RESISTANCE | MECHANISMS | SENESCENCE | EGFR(T790M) | AZD9291 | EGFR INHIBITOR
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 07/2019, Volume 62, Issue 15, pp. 7302 - 7308
Tertiary EGFRC797S mutation induced resistance against osimertinib (1) is an emerging "unmet clinical need" for non-small cell lung cancer (NSCLC) patients. A... 
LUNG-CANCER | EGFR INHIBITORS | GEFITINIB | CHEMISTRY, MEDICINAL | RESISTANCE | OPTIMIZATION | MUTATIONS | DISCOVERY | AZD9291
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2017, Volume 376, Issue 7, pp. 629 - 640
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6523 - 6535
Purpose: Lung cancer is the leading cause of cancer-related death. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and over 60% express... 
TRIAL | GEFITINIB | THERAPY | GROWTH-FACTOR-RECEPTOR | ONCOLOGY | CHECKPOINT | AURORA KINASE | CHEMOTHERAPY | ERLOTINIB | AZD9291
Journal Article
Molecular cancer therapeutics, ISSN 1535-7163, 01/2019, Volume 18, Issue 1, pp. 112 - 126
The critical T790M mutation in EGFR, which mediates resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKI; gefitinib, erlotinib, and... 
CELL LUNG-CANCER | HETEROGENEITY | ONCOLOGY | ADENOCARCINOMA | MUTATION | TYROSINE KINASE INHIBITOR | GENE AMPLIFICATION | RECEPTOR | MECHANISMS | AZD9291 | CHEMOTHERAPY
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6195 - 6203
Purpose: Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant... 
CELL LUNG-CANCER | 1ST-LINE TREATMENT | PIK3CA MUTATIONS | AMPLIFICATION | INHIBITION | ONCOLOGY | ADENOCARCINOMA | PHASE-III | ACQUIRED-RESISTANCE | AZD9291 | ERLOTINIB
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 11/2018, Volume 9
The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients... 
CELL LUNG-CANCER | GEFITINIB | ACTIVATION | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | T790M | MECHANISMS | MUTATIONS | AZD9291 | GENETIC ALTERATIONS | KINASE DOMAIN
Journal Article
ACS Medicinal Chemistry Letters, ISSN 1948-5875, 01/2016, Volume 7, Issue 1, pp. 2 - 5
In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the... 
GEFITINIB | CHEMISTRY, MEDICINAL | MUTATIONS | EGFR | ERLOTINIB | AZD9291
Journal Article
by Wang, YB and Li, L and Han, R and Jiao, L and Zheng, J and He, Y
LUNG CANCER, ISSN 0169-5002, 04/2018, Volume 118, pp. 105 - 110
Introduction: The efficacy of osimertinib was compromised by the development of resistance mechanisms, such as MET amplification. However, cohort studies of... 
Resistance | Crizotinib | LUNG-CANCER | EGFR INHIBITORS | MECHANISM | ONCOLOGY | RESPIRATORY SYSTEM | DNA | MUTATION | Osimertinib | MET amplification | AZD9291
Journal Article
Cancer Discovery, ISSN 2159-8274, 2014, Volume 4, Issue 9, pp. 1046 - 1061
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2016, Volume 22, Issue 19, pp. 4837 - 4847
Journal Article
Nature Medicine, ISSN 1078-8956, 03/2016, Volume 22, Issue 3, pp. 262 - 269
Journal Article